



References

1. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, et al. (2017) 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 38: 2739-2791.
2. Vranckx P, Windecker S, Welsh RC, Valgimigli M, Mehran R, et al. (2017) Thrombo-embolic prevention after transcatheter aortic valve implantation. *Eur Heart J* 38: 3341-3350.
3. Dangas GD, Tijssen JGP, Wöhrle J, Søndergaard L, Gilard M, et al. (2020) A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. *N Engl J Med* 382: 120-129.
4. De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, et al. (2020) . *N Engl J Med* 382: 130-139.
5. Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, et al. (2021) Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. *Eur Heart J* 42: 2265-2269.
6. Collet JP, Berti S, Cequier A, Belle EV, Lefevre T, et al. (2018) Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial.
7. Montalescot G (2021) Apixaban and valve thrombosis after transcatheter aortic valve implantation: the ATLANTIS 4D-CT substudy.
8. Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, et al. (2018) Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. *Am Heart J* 200: 44-50.
9. Chakravarty T, Søndergaard L, Friedman J, De Backer O, Berman D et al. (2017) aortic valves: an observational study. *Lancet* 389: 2383-2392.
10. Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, et al. (2015) . *N Engl J Med* 373: 2015-2024.
11. Giustino G, Tijssen J, Windecker S, Dangas G (2020) Rivaroxaban after transcatheter aortic valve replacement: the GALILEO trial. *Cardiovasc Res* 116: e39-e41.
12. Nishimura RA, Holmes DR, Jr (2020) Treatment after TAVR - Discordance and Clinical Implications. *N Engl J Med* 382: 193-194.